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Resu/~: Lq~l measurements were: total chol~J~tefol (C) 219 ± 38 mg/dl, 
HDL.C 42 ± 11 mg/dl, LDL-C 146 ~: 35 rng/dl, Tnglycerldes 73 ~. 42 m~'dt, 
Lq0~! mo~lymg ll~a~y ~ ~ in 210 pat~e~m (33%) w~th 185 patients 
(29%) taking slatms or flbrat~ alone, Two of morn agents were u ,~ to med+ty 
Nrnmt ~ m 16 patttmlS (2.5%), Utlt¢i~l 1997 AlIA gu~lefines, 447 pat~ent~ 
(7o%) ~ requ~e furm~ ~ mod~r,g t~mpy as LOL.C ¢o~t~r~ 
Of I00 patmnls who had undmgone¢ofonaqf artery by l~ 9 ,~ng (CAOG), 
6~ MdaI~Um LOL.C ~130m0/dl ar~191 ipatle~ts had a sen~n LOI..C ~!00 
m0~+ Slalm o~ Itlwat+ dmm~ we+~ reed m ~ pamml= wm'~ o~e Imt~ race+v- 
melt lwo Imtle~+ 
mm~e ~ ~ mmmmm ,+ mm,~ ~ m mime+ mmmm 
alltml~m ink- 
~ ~ ¢ f  k .m ~n Ik~mm 
M.H, ID, lilS~$o~, K+C, Maki't, H.H ~Itmmcl~t~, J. 0 " ~  . '  ~ C, emer 
k x , ~ ~  ~ ~ U S ~ z ~ ~  Conmmw~ 
B~rgmaz,~" 4HPMC) =s a semm/nlhe~ pelysa¢+ 
c~mde t~'m~ forum ~ ge~ m N 0mmmnemma, w ct. ~ .s  m=mtam 
! o ~  and lemsemalmn, The pu~¢~e t ~ ~ eoul~e-.l~m~ 
p~a~o-¢e,,W~ed study was ~ evsk~e ~e a~r~ of m~ee dine ~ of 
HPl~IC to feclu~ LO~ ct to~l~ m men a~:h,~¢~en with f f~ld-to-modera~ 
rmma~. ~ (Lm. ~ 130--,~0 mgtdL). 
Mea~01s.- N~r at least O weeks on a NabonaJ Cho~kml~ol ~ I~o- 
~ S~S~ I d,e~ tl~O imn=immm ,m~re ramlkm~ a==~r~ed Io ono of lout 
tmaueem arms: ~ 4cell, _,~,~) m ~ a~ doses ol 2.5 9 qd (w~h l~e 
moma~ meal), 2.5 9 I~L o~ 3.75 9 I~I fo+ a 6-~,~ek ~ l~nod. HPMC, 
m l>~,~c-,-ed fo~m was ~ mm an o ~  dnnk taken at n~al 
lime. 
Res~/~- LOL cho~eslen~ e-~x,,-,ses (~ ± SD) ~ -3.4 ± 8.0% 
(placebo), -6.7 :~ 10.2% (2.5 9 q~ P > 0.05 vs. placebo). -13.2 ± 12.0% 
42.5 g bid. p < 0.001 vs. ~ ) ,  a~d -11.9 ± 109% 4375 9 bid, p < 0.001 
vs. ~ ) .  No ~/',,~,~-~.~s between ~ were obsen~d for HDL cho~es- 
tem~ and teglycende n~0,mms, or me modenco of gmm0~,:s~,~ and omer 
advsme experiences. 
Co~ctusk~s.- M closes of 25 g b~d and 3.75 g I~dL HIP,¢~C was ~=11 tcterated 
and ~ re¢luced LDL ct~oh~eroL Ihus may be a useful a(~onct to da~1 
fo~ the management of nald-to-moderade ptm~anj t ~ e ~ e ~  
~ T e n  Yearn of Simvasiat~ Tre=Imenl in F.mpedem:e 
M=rked ~ 
A.G. OP, son. J. M+mgaatd+ De~o~Me~mmme & Cam. Facu~ o~ ~'~,a/~ 
~okgreur=d: HMGCoA reductase ml~ibdor5 (statms) are increasingly used 
to lower elmrated low density lqX)l~rOl~n (LDL) cholesterol ~ Io presumer 
corenary Oisease. Long*erm safety a~l elftcacy ~ata (morn than 5 years) are 
scarce ~ non-emsting f~ tt~ stattns. 
Melt~ls: Simvestatin was ~ for 120 mon~ to 57 patients (36 males) 
~th immary I ~  ol wltom 30 were ~ to ha~e fam~tml 
hypercholesterelemia. Treatment was given first as per protocol and after 
two veam as compassionate use+ Treatment was monitored by the same 
physicians and research nurse through the ten years from 1986 to 1996 at 
n =,.~nthly in,'ewals at start, then even/six month. Mean pat~=nt age at start was 
53 (range 30-74) years. 
Resutts: After 10 years 17 patients had dropped out+ Slmvastatm dose 
ranged from 10 to 60 mg daily. Mean body we+gl~l increased by 3 kg. Mean 
baseline total and LDL cholesterol were 310 ± 81 (SO) and 245 :E 76 moj'dt, 
respe~vely. Total and LOL cholesterol decreased immediately on simvastatin 
and stayed constantly at this low level through ttte 10 years. At 120 months 
plasma total and LDL cholesterol was 32 and 38% lower than baseline. The 
percentage number of patients reaching tl~e LDL targets of 200, 123 and 96 
mg/dl at 120 months were 85, 20 and 3, respectively. Szmvestatin was well 
tolerated subjectively dudng the whole trial length. Increases in s-ALAT and 
s-ASAT activities were seen at seldom occasions and evenly spread over the 
period of treatment. No CK-elevaUon 10x the upper normal imit was seen. No 
cases of myopathy were noted. 
Conclusion: Ten years of simvaststin treatment in marked hypercholes- 
temlemia show that the drag is an effective hypochctestemlemic agent with 
few subjective or objective side effects. The drag seems well suited for long 
term preventive use against coronary disease. 
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" " , Mu~-'~, Gemw~ 
W~ h'w~t~gat~d th~ i ~  of Lova,~a~n an~ V~m~ E ~ 
t ,~  (~g~ ~ ~: O yearn, 11~ me~) who wxW~,mt C,~BO, PatW~ mcw~l  
L ~  (gfl~p t0 n =~ 3B) and ~ l m  plt~ V~n E (gRip 2, n =45) fo~ 
ve~x! t~ um~ ~ depe~ ~ me gene~ pmmm~ (m~up ~)+ 3+4 
graf~ (tOP internal mamma~ af1~y pMA| ~d ~OS veto g~)  m ~ 
b y ~  ~38,  ~amt  at 10e ± 8 we~ aae . ,~/ .  
~ :  Two yum a~ler m~lew, mere ~ a ~ m(Mmo, ot 
Cho~e,~,  t-DL.C an~ ~ n  B l~mm~en ~ 3 ~ (m ~ 
fo~ L~,<~: mdgctmn at mon~ 24), P!menls ol 9mups 1 and 2 ~ a e~fi~ 
ca~ ~ ~ ol gmtt o~du~on but mere vau ~o ~ 
~tlefe~= ~ 1o ~ cam treated pa~.  
I ( t .~)  10~ z 21 10~z5 ~.t== ;) tt30 (3%) 
II (LOva -,, V~ E) 10~ t 27 12R~7 t1B'~, | 1/31~ (3'%) 
In I~  ~)  I~  :~ ~ le/'~ |~l~'~ I 5/43 (1~)  
~005 ~0.05 ~005 
C.o~-~mon: These data ~ real Lovestatm alone was able to 
,~e  commm/graft petency 2 yearn after su~ge~. We fou~l no ~ 
etlecl ol Vmmm E ,*h~,~ adnmslm~ logemer w~h Lovamlm. 
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IEmlotlltehi ~ ~ ~ With C l le~ Pakt: 
Pgot Flunm Cmta Fmm the NNLIBI Women's 
Imchemla S ~  Evaluation (WISE) 
FLA. Kmensky, L Lm, A. Boyeffe, JF. Lewm, S P ~ ,  BL  Sharat, 
C.N. BaJrey Met'z, C.J. Pepme. ~ o f ~  Game.s~/~ F/or/d~ 
USA 
~ .  to pmoo~namty male Sublects. system¢ and ~ ~ 
rml dysfurctmn am essocmted wdh CAD a~dtor CAD ,sk factora. This a~,x.~- 
abort has not been slu0ied m wOmellL 
Me~maS: In 29 womon wfftt chest pare. the mtabom~ between coronary 
( ~  by quamtat~ com~W ang+ugrap~ ~ [~I )  =~ 
brach~ ~eW ([BA| ~gh ~mkmo~ =~a:~xJ  bekYe and a~r ~e.~ma)  
eedornef~l lurctinn was mBmmed. 
~ .  Mean age was 56.1 440-7"3) ~.  H~sto~y ot hypam~,--~;-~ on- 
¢u~ed in 62%. tot~:oo use 55%, ~ i a  55%, fame/~ C./~ 45% InK! 
cflabetes I0%. Coronary endom~ dysfuncth0n (fa~ure to dilate with/Oh) 
was foond m 79% (23r29) w~e BA e~dom~ ~ (no fk~'H~edl- 
atod o~ia~on) occum~ in only 31% (~I~), A,T,,~-,Cj women ~ BA endothelial 
~ .  55% (.5/9) also Pad coronary endomel~ ~ .  However, 
in women w~ normal BA ~-~,thel~al functmn only 10% (2/20) had nom~l 
coronary eedothet~al fur~to~. Thus, a conoo~nt brach~l and ~- ,a ry  e~- 
doff~lial respo~,lse was seen in octy 24% (7F29). 
Conc/us/on: In women with chest pain and muttiPte CAD risk 1actom. corn" 
nan/endomel~ m frequent (79%). ~ not ~ l y  ~ted  
w=th systemK: endothel~ d ~ .  Hence. the a...,u.;octatton bet'~L'e~ sys- 
temic and coronary endothelial funo~o~ in women may be different han m 
men. 
~ C~ronk: Oral Supplement  of Vitamins.Improves 
Endothelial Function in Chronic SmoKers 
H. Etsut~. Y. Matsushima, M. Ayaon. H. Kusano. A. Hamabe. A. Uet~ta. 
B. Takase, A. Kurita, H. Nakamur'd. ~ Defense Mee~c~l Co#ege and 
Serf Defense Fome Central Hos~tal. Sa#ama nd Tokyo, Japan 
Endothelial function is known to be impaired m chro~c smokem po~t f  by 
o~o/gen-dem,'ed flee radicals. [T, etary supplement of antioxiOant vitamins may 
prOwde protec0on against endoth~i;~=! dysfunction. To investigate whether 
320A ,IAC(' I;¢!',, ilal'), lqqX 
chronic combined admlntstrati13n of vit13mln C and E can improve 13nd13th13- 
11131 function, we menaur13d f113w-mod113ted v,3nedl113tten (FMD, endotheltum- 
depend13nt vasedl113tlon) 13nd subtlngual glyc13ryl trinltmt13 Induc13d v~seddation 
(0,3 ms, GTN-D, ondothelium Independent vnsodilntton) In the brnchlnl ndery 
in 11 young chronic smok13rs aged 25 L 3 yeats by high rosolullon ultrttsou13d, 
FMD was m13asurod ,~s percent dt13meter chnngos from baseline to hyp13romlc 
conditions (1 mln ~lfter 5 sin occlusion of femerm artery), Each subjocle, had 
neither the other eomnnn/risk 113c(13m nor org,:lnlc dlseaso, FMD nnd GTN.D 
wore examined 0 limos in each ,ublect; at baseline, nf Iho end of 4 weeks 
oral administration of vitamin C (~ 9/dRy) rmd vitamin E (500 rag/day) 13nd Rt 4 
weeks alter cessation of vitamins, FMD wee slgniflc~ntly increased from u,~se. 
line In the treatment phase 13f vitamins and returned to baseline levels alter 
the oe.s~,~tlon, Vitnmtns had no affect on GTN.D, In ¢onclust13n, chronic corn. 
binod dleti't W t~Llpplomont of vitamin C ~nd E improves endothelial |unction 
nnd might h~vo provenlivo effect against the pmgret'~si13n of nthorasclorasis in 
smokes, H13w~ver, this bonefic~N 13fleet wt~ff rover~od ~fter cossnti13n, 
I~lll¢~etl~no Vd~mlns FIU 
FMD(%) 3~ t ~3 t~,7 ! ~1~' ,tt ~ 16 
GTN.I~ (%1 t~l  14(~ t32 lS4  t4t t,3a 
~ ]  The Determination of Peripheral Flow Mediated 
Vasodll~tlon Is a 8anoltlvo and 9pe¢~lfle Predl¢~tor 
fo r  the Presence o! Coronary Artery Dlee~ne 
~, ~lchroeder, M, Enderle, ROssen, A L~laumbelcb, C HeKteg, M, Plohl, 
K,K. Hesse, H,U, Hearing, K,R, K~mcJ~ FACC, FESC, Univer.'¢~fl, et
Tttpbln~n, GP~m~In~, 
B~Ickgmund: Penpher131 End131heltal Dysfunclton tED) q~,~anlihod by the do. 
termination of Flow Mediated Dilation (FMO%) of the brachtat artery usmg 
hlgh-rasohdion ultrasound has boon ~podod to be an early marker of athoro- 
n~lemsts, Although a poo~itlvn corml,~tion with Coronmy Artery Disease (CAD) 
m discussed, lt~e potentiality ef FMD% to predict presence o¢ absence of CAD 
was to evaluate 
Meth('~'~: In this pro,'~pccflvo, doub113.bllnd 13tudy we moasuiod FMD% as 
a marker of E D, Wn sh~d~od 122 patients without peer tnvas=ve coronary ding- 
oestic13 who were .~ch13dulod lot co[an~lry anglog~aphy because of the clinical 
s~,~.~pi~....~ of CAD (sO~ 80 m/34 f, ,3go 66 t 8.6 yearn, BMI 27.0 ~ ks!m;') 
Boforo cometary anglegraphy, FMD% was measured using h~gh-resolut=on 
uttr~l.~ound (13 Mhz). LongttudinN scans of the brachial arto~ were done on 
B-sod13 • 10 cm above the elbow, at ro~t, dunng roact=vo hyperemia and after 
sublingual admm=strahon of nitrogtyconno. We defined ED as FMD 4,5%. 
The presence of CAD was dehned es angtograph~eally vlowable lesions of 
any dogn.',o. Stat*stlcal analysis was portonnod by t-test, numbers are g~ven 
as moans  t ~r3, 
Re,~ults: Patients wilh CAD had a significantly lower FMD"o than ~'~banls 
wdhout CAD (37 t 41% vs 70t ~ EI,5'~o, p-value . 0.001) Based en FMD 
,45% as a cut-oil point tot ED a s~,nsitivity of 0.71 (72/I01), a specdicily 
Of O,Rl i17t21), a positive predictive value el 095 (72/'/'6) and a negatwo 
predictive value oi 0.37 (11/461 was calculated. 
Conclusions: The non-invasivo determination of Penpheml Endothelial 
Dysfunction according to ~mp~ired Flow Mediated Vasodilatien of the braehial 
~dory w~s found to be n specific and sensitive method to predict the pros- 
once of CAD. This approach warronts further evaluation to determine its role 
as an additional screonmg test to standoff1 methods in patients with chmcal 
suspicion of CAD, 
• Determination of Time to Maximal Flow-mediated, 
Endothelial-dependent Vasodilator Response of the 
Brachlal Artery 
J.A. Arrowood, R. Feozor, M,R. Fisher, P.V. Ravindra, R,G. Makhoul, 
J V. Nixon. Me~ Coil of VA, Richmond. VA. USA 
Measurement of the change m brachial artery diameter (BAD) by high reso- 
lution ultrasound in response to hyperemia can be used to assess endothe- 
hal-dependent vasodilation. The point in time when the maximal vasedilatory 
response occurs has not been well characterized. 
Objective. To determine the time course of vasodilation by measuring BAD 
every 5 sec for 90se~s after distal hyperemia created by 4 .~ sin of for¢arm 
circulatory arrest. 86 SUblects we.re studied 22 to 61 yrs in agu including 49 
(57%) with ask facto~; for CAD 
Results: are shown in the histogram. Average maximum % dilation was 
93 ~t: 19%, Only 45% of patients had maximal BAD 45-60 sec post stimulus, 
whereas 91% reached maximal BAD between 25-70 sec. 
Conclusion: Contrary to accepted practice, BAD should be measured con- 
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~42-5~_ EffQct of Melatonln on Vaacular Rea=t!vlty; 
- - - - -  A Croaa-over Double Blind Study In 
Po=t, menopauaal Women 
M.G Mod013~, R R13ss|, R Molln~n, N Muir, G. Oegttam, F. C~onml, 
A, Andes, A, C~slelh Dpt of Card,gigs k It, Unwe:s~t],, ot & ~ ,  ttah/ 
B~ickgrouf}d Melatan,n (MELt is a natural hoffnone with seVoral sl.ip.~osed 
v0so~¢ftve praporbes 
&.fethect~ In order to test the effects el MEL on the en(lothehal function 
we podenned a double bhnd cross-ovo~ study versus placebo ~n 18 Consec- 
uhve posheen13p~usal women (mean age: $3.24 t 4.24 years) Wome. with 
diabetes, hypertension, I~yporchotosteralem~ a:,d smokers were exek~k.--,d 
E13ch woman was randomized to oral placebo or MEL at the dose o! I mg and 
the day after crossed.over to the opposite treatment. Endothelial dependent 
v{~sodilaflon was studied. I hour ~lte~ the assumption o1 the drug, by mes- 
sy.inns the changes in brachiat artery dlamotor (BAd) and IIow attar reacttve 
hypotom~a Endothelial mdependcnt vasodllat~on was measured 3 mmutes 
alter 400 ~ g of spray subhngual mtmgfycenn 
ResultS; 
~..~.abtes Placebo MEL p 
BAll. ms. base 4 r t 13 4 408 ~ 13 5 O 8 
ioacttvo hyporomlll 4 a t 13 4 4 ~ t O 6 0 6 
atlo~ ntbostyc,elm 5 e t 13 4 4 I~O .. e 4 0 2, 
now mediated ilation 8 2 t 4 I 15 4 I 6 t e 135, 
Flow. mr(ms, t~)so 50 3 ~ 16 O t4 4 ~ 25, | O 05, 
reactive hypo~omta 765, : 26 13 75, 5, ~ 25 0 138 
¢'~ltov nltloglycerm 53 6 ~ 23 0 556 ~ 10 O O 6 
Conclusten: MEL seems to have a positive inlluenco on endolhehal depen- 
dent vasoddabon 
~_~]  Cholesterol Lowering With Pravastatin Improves 
Resistance Artery Endothelial Function in Subjects 
With Normal Coronary  Ar ter iograms 
J.L. Houghton, EF. Phdbin, M.T. Torossov, R.G. Reed, T.A. Pearson. Albany 
Medical College. Albany, NY, USA 
Background Improvement in epicard~al and resistance coronary endethehal 
function after cholesterol Iowenng has been demonstrated in pts with overt 
CAD but not in hyperchotesterolemic pls with nl cor. 
Methods: Twenty-four euglycemic pts with elevated LDL chol ( : 130 mg~dl) 
were placed on an AHA lipid Iowenng diet for 12 wks and then underwent 
baseline endothelial function k;sting utilizing graded intracoronary infusions 
of ACh. 
Results: Of 24, 14 {58%) were tound to have an abnormal resistance artery 
ddator response to ACh I. 150°o increase) and were candidates for random- 
tzation. One subject was not randnmlzed becaus~ of dietary noncompliance. 
The remaining 13 were ranaomly assigned in a double blind fashion to recewe 
either pravastatin (20--40 mg per day) or placebo for 6 months. Endothelial 
function testing was then repeated using the identical protocol. Of 8 pts re- 
ceiving pravastatin, peak increase in coronary blood flow (CBF) was 97 
10°,o at basehne and 140 :.~ 18% during restudy (p = 0.06). In six of these 
with nlcor, peak increase in CBF was 97 ~ 13% at baseline and 160 ± 16% 
after p, ~vastatin (p = 0.01). LDL chol was 151 ~. 8 at baseline and 112 ± 7 
mgldl at restudy (p = 0.005), Of 5 receiving placebo, 2 were excluded; one 
because of a technically poor study and one because of noncompliance, In 
the 3 placebo pts, peak CBF responses were 110 ± 16% and 120 ± 27% 
increase, respectively (p = NS). LDL chol was unchanged at 182 ± 14 and 
187 ~ 18 mg/dl, 
Conclusion: Treatment with pravastatin over 6 mGnt:~s led to significant 
lowering of LDL chol a,~d improved resistance artery ,,ndothelial function 
among pts with nl cor. Pt~cebo controls did not show this Oenefit. 
